1	Signal	Signal	_	_	_	_	_	_	_
2	transduction	transduction	_	_	_	_	_	_	_
3	abnormalities	abnormality	_	_	_	_	_	_	_
4	in	in	_	_	_	_	_	_	_
5	T	t	_	_	_	_	_	_	_
6	lymphocytes	lymphocyte	_	_	_	_	_	_	_
7	from	from	_	_	_	_	_	_	_
8	patients	patient	_	_	_	_	_	_	_
9	with	with	_	_	_	_	_	_	_
10	advanced	advance	_	_	_	_	_	_	_
11	renal	renal	_	_	_	_	_	_	_
12	carcinoma	carcinoma	_	_	_	_	_	_	_
13	:	:	_	_	_	_	_	_	_
14	clinical	clinical	_	_	_	_	_	_	_
15	relevance	relevance	_	_	_	_	_	_	_
16	and	and	_	_	_	_	_	_	_
17	effects	effect	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	cytokine	cytokine	_	_	_	_	_	_	_
20	therapy	therapy	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	Studies	Study	_	_	_	_	_	_	_
2	have	have	_	_	_	_	_	_	_
3	demonstrated	demonstrate	_	_	_	_	_	_	_
4	abnormalities	abnormality	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	CD3/T-cell	cd3/t-cell	_	_	_	_	_	_	_
8	antigen	antigen	_	_	_	_	_	_	_
9	receptor	receptor	_	_	_	_	_	_	_
10	(	(	_	_	_	_	_	_	_
11	TCR	TCR	_	_	_	_	_	_	_
12	)	)	_	_	_	_	_	_	_
13	and	and	_	_	_	_	_	_	_
14	pathways	pathway	_	_	_	_	_	_	_
15	of	of	_	_	_	_	_	_	_
16	signal	signal	_	_	_	_	_	_	_
17	transduction	transduction	_	_	_	_	_	_	_
18	in	in	_	_	_	_	_	_	_
19	T	t	_	_	_	_	_	_	_
20	lymphocytes	lymphocyte	_	_	_	_	_	_	_
21	from	from	_	_	_	_	_	_	_
22	animals	animal	_	_	_	_	_	_	_
23	and	and	_	_	_	_	_	_	_
24	patients	patient	_	_	_	_	_	_	_
25	with	with	_	_	_	_	_	_	_
26	advanced	advanced	_	_	_	_	_	_	_
27	malignancy	malignancy	_	_	_	_	_	_	_
28	.	.	_	_	_	_	_	_	_

1	Diminished	diminish	_	_	_	_	_	_	_
2	expression	expression	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	TCRzeta	TCRzeta	_	_	_	_	_	_	_
5	and	and	_	_	_	_	_	_	_
6	p56(lck)	p56(lck)	_	_	_	_	_	_	_
7	that	that	_	_	_	_	_	_	_
8	are	be	_	_	_	_	_	_	_
9	associated	associate	_	_	_	_	_	_	_
10	with	with	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	TCR	TCR	_	_	_	_	_	_	_
13	and	and	_	_	_	_	_	_	_
14	reduced	reduce	_	_	_	_	_	_	_
15	nuclear	nuclear	_	_	_	_	_	_	_
16	localization	localization	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	RelA	RelA	_	_	_	_	_	_	_
19	containing	contain	_	_	_	_	_	_	_
20	nuclear	nuclear	_	_	_	_	_	_	_
21	factor	factor	_	_	_	_	_	_	_
22	kappaB	kappaB	_	_	_	_	_	_	_
23	(	(	_	_	_	_	_	_	_
24	NFkappaB	NFkappaB	_	_	_	_	_	_	_
25	)	)	_	_	_	_	_	_	_
26	complexes	complex	_	_	_	_	_	_	_
27	have	have	_	_	_	_	_	_	_
28	been	be	_	_	_	_	_	_	_
29	noted	note	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	These	these	_	_	_	_	_	_	_
2	defects	defect	_	_	_	_	_	_	_
3	have	have	_	_	_	_	_	_	_
4	been	be	_	_	_	_	_	_	_
5	described	describe	_	_	_	_	_	_	_
6	in	in	_	_	_	_	_	_	_
7	T	t	_	_	_	_	_	_	_
8	cells	cell	_	_	_	_	_	_	_
9	from	from	_	_	_	_	_	_	_
10	patients	patient	_	_	_	_	_	_	_
11	with	with	_	_	_	_	_	_	_
12	malignant	malignant	_	_	_	_	_	_	_
13	melanoma	melanoma	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	renal	renal	_	_	_	_	_	_	_
16	cell	cell	_	_	_	_	_	_	_
17	carcinoma	carcinoma	_	_	_	_	_	_	_
18	(	(	_	_	_	_	_	_	_
19	RCC	RCC	_	_	_	_	_	_	_
20	)	)	_	_	_	_	_	_	_
21	,	,	_	_	_	_	_	_	_
22	ovarian	ovarian	_	_	_	_	_	_	_
23	cancer	cancer	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	and	and	_	_	_	_	_	_	_
26	colorectal	colorectal	_	_	_	_	_	_	_
27	cancer	cancer	_	_	_	_	_	_	_
28	.	.	_	_	_	_	_	_	_

1	Preliminary	preliminary	_	_	_	_	_	_	_
2	observations	observation	_	_	_	_	_	_	_
3	also	also	_	_	_	_	_	_	_
4	indicate	indicate	_	_	_	_	_	_	_
5	possible	possible	_	_	_	_	_	_	_
6	correlation	correlation	_	_	_	_	_	_	_
7	with	with	_	_	_	_	_	_	_
8	clinical	clinical	_	_	_	_	_	_	_
9	variables	variable	_	_	_	_	_	_	_
10	such	such	_	_	_	_	_	_	_
11	as	as	_	_	_	_	_	_	_
12	stage	stage	_	_	_	_	_	_	_
13	in	in	_	_	_	_	_	_	_
14	selected	select	_	_	_	_	_	_	_
15	instances	instance	_	_	_	_	_	_	_
16	.	.	_	_	_	_	_	_	_

1	To	to	_	_	_	_	_	_	_
2	further	further	_	_	_	_	_	_	_
3	characterize	characterize	_	_	_	_	_	_	_
4	altered	altered	_	_	_	_	_	_	_
5	expression	expression	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	TCRzeta	TCRzeta	_	_	_	_	_	_	_
8	,	,	_	_	_	_	_	_	_
9	p56(lck)	p56(lck)	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	impaired	impaired	_	_	_	_	_	_	_
13	activation	activation	_	_	_	_	_	_	_
14	of	of	_	_	_	_	_	_	_
15	NFkappaB	NFkappaB	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	T	t	_	_	_	_	_	_	_
18	lymphocytes	lymphocyte	_	_	_	_	_	_	_
19	were	be	_	_	_	_	_	_	_
20	obtained	obtain	_	_	_	_	_	_	_
21	from	from	_	_	_	_	_	_	_
22	65	65	_	_	_	_	_	_	_
23	patients	patient	_	_	_	_	_	_	_
24	with	with	_	_	_	_	_	_	_
25	RCC	RCC	_	_	_	_	_	_	_
26	,	,	_	_	_	_	_	_	_
27	the	the	_	_	_	_	_	_	_
28	majority	majority	_	_	_	_	_	_	_
29	of	of	_	_	_	_	_	_	_
30	whom	whom	_	_	_	_	_	_	_
31	were	be	_	_	_	_	_	_	_
32	receiving	receive	_	_	_	_	_	_	_
33	combination	combination	_	_	_	_	_	_	_
34	cytokine	cytokine	_	_	_	_	_	_	_
35	therapy	therapy	_	_	_	_	_	_	_
36	[	[	_	_	_	_	_	_	_
37	interleukin	interleukin	_	_	_	_	_	_	_
38	(	(	_	_	_	_	_	_	_
39	IL)-2	IL)-2	_	_	_	_	_	_	_
40	,	,	_	_	_	_	_	_	_
41	IFN	ifn	_	_	_	_	_	_	_
42	alpha-containing	alpha-containing	_	_	_	_	_	_	_
43	regimens	regimen	_	_	_	_	_	_	_
44	]	]	_	_	_	_	_	_	_
45	and	and	_	_	_	_	_	_	_
46	37	37	_	_	_	_	_	_	_
47	control	control	_	_	_	_	_	_	_
48	individuals	individual	_	_	_	_	_	_	_
49	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	29	29	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	these	these	_	_	_	_	_	_	_
5	patients	patient	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	levels	level	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	TCRzeta	TCRzeta	_	_	_	_	_	_	_
10	and	and	_	_	_	_	_	_	_
11	p56(lck)	p56(lck)	_	_	_	_	_	_	_
12	were	be	_	_	_	_	_	_	_
13	determined	determine	_	_	_	_	_	_	_
14	by	by	_	_	_	_	_	_	_
15	Western	western	_	_	_	_	_	_	_
16	blots	blot	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	T-cell	t-cell	_	_	_	_	_	_	_
19	lysates	lysate	_	_	_	_	_	_	_
20	and	and	_	_	_	_	_	_	_
21	semiquantitated	semiquantitate	_	_	_	_	_	_	_
22	using	use	_	_	_	_	_	_	_
23	densitometry	densitometry	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	Relative	relative	_	_	_	_	_	_	_
2	levels	level	_	_	_	_	_	_	_
3	were	be	_	_	_	_	_	_	_
4	then	then	_	_	_	_	_	_	_
5	correlated	correlate	_	_	_	_	_	_	_
6	with	with	_	_	_	_	_	_	_
7	a	a	_	_	_	_	_	_	_
8	series	series	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	clinical	clinical	_	_	_	_	_	_	_
11	variables	variable	_	_	_	_	_	_	_
12	including	include	_	_	_	_	_	_	_
13	response	response	_	_	_	_	_	_	_
14	to	to	_	_	_	_	_	_	_
15	therapy	therapy	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	performance	performance	_	_	_	_	_	_	_
18	status	status	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	survival	survival	_	_	_	_	_	_	_
21	,	,	_	_	_	_	_	_	_
22	disease	disease	_	_	_	_	_	_	_
23	sites	site	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	age	age	_	_	_	_	_	_	_
26	,	,	_	_	_	_	_	_	_
27	and	and	_	_	_	_	_	_	_
28	others	other	_	_	_	_	_	_	_
29	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	another	another	_	_	_	_	_	_	_
3	group	group	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	28	28	_	_	_	_	_	_	_
6	patients	patient	_	_	_	_	_	_	_
7	(	(	_	_	_	_	_	_	_
8	three	three	_	_	_	_	_	_	_
9	individuals	individual	_	_	_	_	_	_	_
10	from	from	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	first	first	_	_	_	_	_	_	_
13	group	group	_	_	_	_	_	_	_
14	)	)	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	frequency	frequency	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	abnormal	abnormal	_	_	_	_	_	_	_
20	NFkappaB	NFkappaB	_	_	_	_	_	_	_
21	activation	activation	_	_	_	_	_	_	_
22	was	be	_	_	_	_	_	_	_
23	studied	study	_	_	_	_	_	_	_
24	using	use	_	_	_	_	_	_	_
25	electrophoretic	electrophoretic	_	_	_	_	_	_	_
26	mobility	mobility	_	_	_	_	_	_	_
27	shift	shift	_	_	_	_	_	_	_
28	assays	assay	_	_	_	_	_	_	_
29	after	after	_	_	_	_	_	_	_
30	activation	activation	_	_	_	_	_	_	_
31	of	of	_	_	_	_	_	_	_
32	T	t	_	_	_	_	_	_	_
33	cells	cell	_	_	_	_	_	_	_
34	with	with	_	_	_	_	_	_	_
35	phorbol	phorbol	_	_	_	_	_	_	_
36	myristate	myristate	_	_	_	_	_	_	_
37	acetate/ionomycin	acetate/ionomycin	_	_	_	_	_	_	_
38	or	or	_	_	_	_	_	_	_
39	anti-CD3	anti-cd3	_	_	_	_	_	_	_
40	monoclonal	monoclonal	_	_	_	_	_	_	_
41	antibody	antibody	_	_	_	_	_	_	_
42	.	.	_	_	_	_	_	_	_

1	Changes	change	_	_	_	_	_	_	_
2	in	in	_	_	_	_	_	_	_
3	these	these	_	_	_	_	_	_	_
4	signaling	signal	_	_	_	_	_	_	_
5	molecules	molecule	_	_	_	_	_	_	_
6	during	during	_	_	_	_	_	_	_
7	cytokine	cytokine	_	_	_	_	_	_	_
8	treatment	treatment	_	_	_	_	_	_	_
9	were	be	_	_	_	_	_	_	_
10	also	also	_	_	_	_	_	_	_
11	investigated	investigate	_	_	_	_	_	_	_
12	.	.	_	_	_	_	_	_	_

1	TCRzeta	TCRzeta	_	_	_	_	_	_	_
2	and	and	_	_	_	_	_	_	_
3	p56(lck)	p56(lck)	_	_	_	_	_	_	_
4	were	be	_	_	_	_	_	_	_
5	detected	detect	_	_	_	_	_	_	_
6	in	in	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	peripheral	peripheral	_	_	_	_	_	_	_
9	blood	blood	_	_	_	_	_	_	_
10	T	t	_	_	_	_	_	_	_
11	cells	cell	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	27	27	_	_	_	_	_	_	_
14	of	of	_	_	_	_	_	_	_
15	29	29	_	_	_	_	_	_	_
16	patients	patient	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	and	and	_	_	_	_	_	_	_
19	overall	overall	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	reduced	reduce	_	_	_	_	_	_	_
22	levels	level	_	_	_	_	_	_	_
23	were	be	_	_	_	_	_	_	_
24	noted	note	_	_	_	_	_	_	_
25	visually	visually	_	_	_	_	_	_	_
26	in	in	_	_	_	_	_	_	_
27	12	12	_	_	_	_	_	_	_
28	of	of	_	_	_	_	_	_	_
29	29	29	_	_	_	_	_	_	_
30	(	(	_	_	_	_	_	_	_
31	41	41	_	_	_	_	_	_	_
32	%	%	_	_	_	_	_	_	_
33	)	)	_	_	_	_	_	_	_
34	and	and	_	_	_	_	_	_	_
35	13	13	_	_	_	_	_	_	_
36	of	of	_	_	_	_	_	_	_
37	29	29	_	_	_	_	_	_	_
38	(	(	_	_	_	_	_	_	_
39	45	45	_	_	_	_	_	_	_
40	%	%	_	_	_	_	_	_	_
41	)	)	_	_	_	_	_	_	_
42	individuals	individual	_	_	_	_	_	_	_
43	,	,	_	_	_	_	_	_	_
44	respectively	respectively	_	_	_	_	_	_	_
45	.	.	_	_	_	_	_	_	_

1	When	when	_	_	_	_	_	_	_
2	levels	level	_	_	_	_	_	_	_
3	were	be	_	_	_	_	_	_	_
4	semiquantitated	semiquantitate	_	_	_	_	_	_	_
5	using	use	_	_	_	_	_	_	_
6	densitometry	densitometry	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	significant	significant	_	_	_	_	_	_	_
9	decreases	decrease	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	TCRzeta	TCRzeta	_	_	_	_	_	_	_
12	(	(	_	_	_	_	_	_	_
13	P	p	_	_	_	_	_	_	_
14	=	=	_	_	_	_	_	_	_
15	0.029	0.029	_	_	_	_	_	_	_
16	)	)	_	_	_	_	_	_	_
17	and	and	_	_	_	_	_	_	_
18	p56(lck)	p56(lck)	_	_	_	_	_	_	_
19	(	(	_	_	_	_	_	_	_
20	P	p	_	_	_	_	_	_	_
21	=	=	_	_	_	_	_	_	_
22	0.029	0.029	_	_	_	_	_	_	_
23	)	)	_	_	_	_	_	_	_
24	but	but	_	_	_	_	_	_	_
25	not	not	_	_	_	_	_	_	_
26	CD3epsilon	CD3epsilon	_	_	_	_	_	_	_
27	(	(	_	_	_	_	_	_	_
28	P	p	_	_	_	_	_	_	_
29	=	=	_	_	_	_	_	_	_
30	0.131	0.131	_	_	_	_	_	_	_
31	)	)	_	_	_	_	_	_	_
32	,	,	_	_	_	_	_	_	_
33	compared	compare	_	_	_	_	_	_	_
34	with	with	_	_	_	_	_	_	_
35	control	control	_	_	_	_	_	_	_
36	levels	level	_	_	_	_	_	_	_
37	,	,	_	_	_	_	_	_	_
38	were	be	_	_	_	_	_	_	_
39	found	find	_	_	_	_	_	_	_
40	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	patients	patient	_	_	_	_	_	_	_
3	treated	treat	_	_	_	_	_	_	_
4	with	with	_	_	_	_	_	_	_
5	IL-2/IFN	il-2/ifn	_	_	_	_	_	_	_
6	alpha-based	alpha-based	_	_	_	_	_	_	_
7	therapy	therapy	_	_	_	_	_	_	_
8	,	,	_	_	_	_	_	_	_
9	relative	relative	_	_	_	_	_	_	_
10	levels	level	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	TCRzeta	TCRzeta	_	_	_	_	_	_	_
13	increased	increase	_	_	_	_	_	_	_
14	significantly	significantly	_	_	_	_	_	_	_
15	(	(	_	_	_	_	_	_	_
16	P	p	_	_	_	_	_	_	_
17	=	=	_	_	_	_	_	_	_
18	0.002	0.002	_	_	_	_	_	_	_
19	)	)	_	_	_	_	_	_	_
20	on	on	_	_	_	_	_	_	_
21	day	day	_	_	_	_	_	_	_
22	15	15	_	_	_	_	_	_	_
23	of	of	_	_	_	_	_	_	_
24	cycle	cycle	_	_	_	_	_	_	_
25	one	one	_	_	_	_	_	_	_
26	compared	compare	_	_	_	_	_	_	_
27	with	with	_	_	_	_	_	_	_
28	the	the	_	_	_	_	_	_	_
29	baseline	baseline	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	Correlations	correlation	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	TCRzeta	TCRzeta	_	_	_	_	_	_	_
4	or	or	_	_	_	_	_	_	_
5	p56(lck)	p56(lck)	_	_	_	_	_	_	_
6	levels	level	_	_	_	_	_	_	_
7	with	with	_	_	_	_	_	_	_
8	response	response	_	_	_	_	_	_	_
9	or	or	_	_	_	_	_	_	_
10	disease	disease	_	_	_	_	_	_	_
11	variables	variable	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	except	except	_	_	_	_	_	_	_
14	for	for	_	_	_	_	_	_	_
15	lower	low	_	_	_	_	_	_	_
16	TCRzeta	TCRzeta	_	_	_	_	_	_	_
17	levels	level	_	_	_	_	_	_	_
18	(	(	_	_	_	_	_	_	_
19	P	p	_	_	_	_	_	_	_
20	<	<	_	_	_	_	_	_	_
21	0.001	0.001	_	_	_	_	_	_	_
22	)	)	_	_	_	_	_	_	_
23	in	in	_	_	_	_	_	_	_
24	the	the	_	_	_	_	_	_	_
25	presence	presence	_	_	_	_	_	_	_
26	of	of	_	_	_	_	_	_	_
27	bone	bone	_	_	_	_	_	_	_
28	metastases	metastasis	_	_	_	_	_	_	_
29	,	,	_	_	_	_	_	_	_
30	were	be	_	_	_	_	_	_	_
31	not	not	_	_	_	_	_	_	_
32	found	find	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

1	Abnormal	abnormal	_	_	_	_	_	_	_
2	NFkappaB	NFkappaB	_	_	_	_	_	_	_
3	activation	activation	_	_	_	_	_	_	_
4	after	after	_	_	_	_	_	_	_
5	stimulation	stimulation	_	_	_	_	_	_	_
6	with	with	_	_	_	_	_	_	_
7	phorbol	phorbol	_	_	_	_	_	_	_
8	myristate	myristate	_	_	_	_	_	_	_
9	acetate/ionomycin	acetate/ionomycin	_	_	_	_	_	_	_
10	and/or	and/or	_	_	_	_	_	_	_
11	anti-CD3	anti-cd3	_	_	_	_	_	_	_
12	monoclonal	monoclonal	_	_	_	_	_	_	_
13	antibody	antibody	_	_	_	_	_	_	_
14	was	be	_	_	_	_	_	_	_
15	found	find	_	_	_	_	_	_	_
16	in	in	_	_	_	_	_	_	_
17	59	59	_	_	_	_	_	_	_
18	%	%	_	_	_	_	_	_	_
19	of	of	_	_	_	_	_	_	_
20	patients	patient	_	_	_	_	_	_	_
21	(	(	_	_	_	_	_	_	_
22	17	17	_	_	_	_	_	_	_
23	of	of	_	_	_	_	_	_	_
24	28	28	_	_	_	_	_	_	_
25	)	)	_	_	_	_	_	_	_
26	and	and	_	_	_	_	_	_	_
27	was	be	_	_	_	_	_	_	_
28	not	not	_	_	_	_	_	_	_
29	accounted	account	_	_	_	_	_	_	_
30	for	for	_	_	_	_	_	_	_
31	by	by	_	_	_	_	_	_	_
32	the	the	_	_	_	_	_	_	_
33	advanced	advanced	_	_	_	_	_	_	_
34	age	age	_	_	_	_	_	_	_
35	of	of	_	_	_	_	_	_	_
36	the	the	_	_	_	_	_	_	_
37	study	study	_	_	_	_	_	_	_
38	cohort	cohort	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

1	Activation	Activation	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	NFkappaB	NFkappaB	_	_	_	_	_	_	_
4	in	in	_	_	_	_	_	_	_
5	peripheral	peripheral	_	_	_	_	_	_	_
6	blood	blood	_	_	_	_	_	_	_
7	T	t	_	_	_	_	_	_	_
8	cells	cell	_	_	_	_	_	_	_
9	was	be	_	_	_	_	_	_	_
10	inducible	inducible	_	_	_	_	_	_	_
11	during	during	_	_	_	_	_	_	_
12	cytokine	cytokine	_	_	_	_	_	_	_
13	therapy	therapy	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	four	four	_	_	_	_	_	_	_
16	of	of	_	_	_	_	_	_	_
17	six	six	_	_	_	_	_	_	_
18	individuals	individual	_	_	_	_	_	_	_
19	who	who	_	_	_	_	_	_	_
20	displayed	display	_	_	_	_	_	_	_
21	impaired	impaired	_	_	_	_	_	_	_
22	NFkappaB	NFkappaB	_	_	_	_	_	_	_
23	activity	activity	_	_	_	_	_	_	_
24	prior	prior	_	_	_	_	_	_	_
25	to	to	_	_	_	_	_	_	_
26	therapy	therapy	_	_	_	_	_	_	_
27	.	.	_	_	_	_	_	_	_

1	Moreover	moreover	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	impaired	impaired	_	_	_	_	_	_	_
4	activation	activation	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	NFkappaB	NFkappaB	_	_	_	_	_	_	_
7	does	do	_	_	_	_	_	_	_
8	not	not	_	_	_	_	_	_	_
9	appear	appear	_	_	_	_	_	_	_
10	linked	link	_	_	_	_	_	_	_
11	to	to	_	_	_	_	_	_	_
12	a	a	_	_	_	_	_	_	_
13	reduction	reduction	_	_	_	_	_	_	_
14	of	of	_	_	_	_	_	_	_
15	TCRzeta	TCRzeta	_	_	_	_	_	_	_
16	expression	expression	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	because	because	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	five	five	_	_	_	_	_	_	_
21	patients	patient	_	_	_	_	_	_	_
22	,	,	_	_	_	_	_	_	_
23	normal	normal	_	_	_	_	_	_	_
24	TCRzeta	TCRzeta	_	_	_	_	_	_	_
25	levels	level	_	_	_	_	_	_	_
26	were	be	_	_	_	_	_	_	_
27	present	present	_	_	_	_	_	_	_
28	although	although	_	_	_	_	_	_	_
29	kappaB	kappab	_	_	_	_	_	_	_
30	binding	binding	_	_	_	_	_	_	_
31	was	be	_	_	_	_	_	_	_
32	not	not	_	_	_	_	_	_	_
33	inducible	inducible	_	_	_	_	_	_	_
34	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	the	the	_	_	_	_	_	_	_
3	majority	majority	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	patients	patient	_	_	_	_	_	_	_
6	with	with	_	_	_	_	_	_	_
7	advanced	advance	_	_	_	_	_	_	_
8	RCC	RCC	_	_	_	_	_	_	_
9	,	,	_	_	_	_	_	_	_
10	peripheral	peripheral	_	_	_	_	_	_	_
11	blood	blood	_	_	_	_	_	_	_
12	T	t	_	_	_	_	_	_	_
13	cells	cell	_	_	_	_	_	_	_
14	express	express	_	_	_	_	_	_	_
15	TCRzeta	TCRzeta	_	_	_	_	_	_	_
16	and	and	_	_	_	_	_	_	_
17	p56(lck)	p56(lck)	_	_	_	_	_	_	_
18	,	,	_	_	_	_	_	_	_
19	and	and	_	_	_	_	_	_	_
20	in	in	_	_	_	_	_	_	_
21	a	a	_	_	_	_	_	_	_
22	subset	subset	_	_	_	_	_	_	_
23	,	,	_	_	_	_	_	_	_
24	reduced	reduce	_	_	_	_	_	_	_
25	levels	level	_	_	_	_	_	_	_
26	of	of	_	_	_	_	_	_	_
27	these	these	_	_	_	_	_	_	_
28	TCRzeta	TCRzeta	_	_	_	_	_	_	_
29	associated	associated	_	_	_	_	_	_	_
30	molecules	molecule	_	_	_	_	_	_	_
31	are	be	_	_	_	_	_	_	_
32	seen	see	_	_	_	_	_	_	_
33	that	that	_	_	_	_	_	_	_
34	may	may	_	_	_	_	_	_	_
35	increase	increase	_	_	_	_	_	_	_
36	during	during	_	_	_	_	_	_	_
37	cytokine-based	cytokine-based	_	_	_	_	_	_	_
38	therapy	therapy	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

1	Abnormal	abnormal	_	_	_	_	_	_	_
2	activation	activation	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	NFkappaB	NFkappaB	_	_	_	_	_	_	_
5	is	be	_	_	_	_	_	_	_
6	also	also	_	_	_	_	_	_	_
7	present	present	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	>50	>50	_	_	_	_	_	_	_
10	%	%	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	patients	patient	_	_	_	_	_	_	_
13	and	and	_	_	_	_	_	_	_
14	may	may	_	_	_	_	_	_	_
15	also	also	_	_	_	_	_	_	_
16	revert	revert	_	_	_	_	_	_	_
17	to	to	_	_	_	_	_	_	_
18	normal	normal	_	_	_	_	_	_	_
19	during	during	_	_	_	_	_	_	_
20	IL-2/IFN	il-2/ifn	_	_	_	_	_	_	_
21	alpha-based	alpha-based	_	_	_	_	_	_	_
22	treatment	treatment	_	_	_	_	_	_	_
23	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	alteration	alteration	_	_	_	_	_	_	_
3	in	in	_	_	_	_	_	_	_
4	NFkappaB	NFkappaB	_	_	_	_	_	_	_
5	activation	activation	_	_	_	_	_	_	_
6	occurred	occur	_	_	_	_	_	_	_
7	in	in	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	presence	presence	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	normal	normal	_	_	_	_	_	_	_
12	expression	expression	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	TCRzeta-associated	tcrzeta-associated	_	_	_	_	_	_	_
15	signaling	signaling	_	_	_	_	_	_	_
16	elements	element	_	_	_	_	_	_	_
17	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	clinical	clinical	_	_	_	_	_	_	_
3	significance	significance	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	these	these	_	_	_	_	_	_	_
6	findings	finding	_	_	_	_	_	_	_
7	remains	remain	_	_	_	_	_	_	_
8	unclear	unclear	_	_	_	_	_	_	_
9	.	.	_	_	_	_	_	_	_

